Uproleselan added to cladribine + LDAC for treated secondary AML: insights from a Phase Ib/II study [Video]

Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses data from a Phase Ib/II study (NCT04848974) evaluating the safety, tolerability, and efficacy of uproleselan added to cladribine and low-dose cytarabine (LDAC) in patients with newly diagnosed treated secondary acute myeloid leukemia (ts-AML) which develops from prior myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMAs). Uproleselan is an e-selectin antagonist, hence the rationale for using it in this patient population, as e-selectin upregulation can occur following HMA treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.